211 related articles for article (PubMed ID: 27168342)
21. Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): from bench to bedside.
Abdel-Rahman O
Crit Rev Oncol Hematol; 2015 Apr; 94(1):45-54. PubMed ID: 25560732
[TBL] [Abstract][Full Text] [Related]
22. Targeted therapy in refractory thyroid cancer: current achievements and limitations.
Brilli L; Pacini F
Future Oncol; 2011 May; 7(5):657-68. PubMed ID: 21568681
[TBL] [Abstract][Full Text] [Related]
23. Initial Treatment of Progressive Differentiated Thyroid Cancer.
Tuttle RM
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):3-6. PubMed ID: 27168341
[No Abstract] [Full Text] [Related]
24. Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy.
San Román Gil M; Pozas J; Molina-Cerrillo J; Gómez J; Pian H; Pozas M; Carrato A; Grande E; Alonso-Gordoa T
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668761
[TBL] [Abstract][Full Text] [Related]
25. Update on thyroid cancer treatment.
Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
[TBL] [Abstract][Full Text] [Related]
26. Lenvatinib (Lenvima) for thyroid cancer.
Med Lett Drugs Ther; 2015 Aug; 57(1475):e120-1. PubMed ID: 26262885
[No Abstract] [Full Text] [Related]
27. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapies for advanced thyroid cancer.
Puxeddu E; Romagnoli S; Dottorini ME
Curr Opin Oncol; 2011 Jan; 23(1):13-21. PubMed ID: 21045687
[TBL] [Abstract][Full Text] [Related]
29. The role of sorafenib in hepatocellular carcinoma.
Gholam P
Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
[No Abstract] [Full Text] [Related]
30. The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies.
Lirov R; Worden FP; Cohen MS
Drugs; 2017 May; 77(7):733-745. PubMed ID: 28361210
[TBL] [Abstract][Full Text] [Related]
31. Trial watch: Multikinase-targeting therapy finds potential niche in thyroid cancer.
Cully M
Nat Rev Drug Discov; 2015 Apr; 14(4):229. PubMed ID: 25829272
[No Abstract] [Full Text] [Related]
32. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
33. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
34. Role of tyrosine kinase inhibitors in the management of high-grade gliomas.
Ahluwalia MS; Patel M; Peereboom DM
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1739-48. PubMed ID: 22050023
[TBL] [Abstract][Full Text] [Related]
35. The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review.
Ntanasis-Stathopoulos I; Fotopoulos G; Tzanninis IG; Kotteas EA
Cancer Invest; 2016 Aug; 34(7):313-39. PubMed ID: 27486869
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
García-Martín A; López-Ibarra Lozano PJ; Triviño-Ibáñez EM; Escobar-Jiménez F
Endocrinol Nutr; 2013 Mar; 60(3):152-3. PubMed ID: 22565118
[No Abstract] [Full Text] [Related]
37. Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma [Review].
Ito Y; Suzuki S; Ito K; Imai T; Okamoto T; Kitano H; Sugitani I; Sugino K; Tsutsui H; Hara H; Yoshida A; Shimizu K
Endocr J; 2016 Jul; 63(7):597-602. PubMed ID: 27210070
[TBL] [Abstract][Full Text] [Related]
38. Multikinase Inhibitor Treatment in Thyroid Cancer.
Ancker OV; Krüger M; Wehland M; Infanger M; Grimm D
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861373
[TBL] [Abstract][Full Text] [Related]
39. Cabozantinib in genitourinary malignancies.
Zhang T; Park SE; Hong C; George DJ
Future Oncol; 2017 Apr; 13(8):755-765. PubMed ID: 27842445
[TBL] [Abstract][Full Text] [Related]
40. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
